Prostate Cancer With Tertiary Gleason Pattern 5 in Prostate Needle Biopsy Clinicopathologic Findings and Disease Progression

被引:30
作者
Trpkov, Kiril [1 ]
Zhang, Jianguo [2 ]
Chan, Melissa [1 ]
Eigl, Bernhard J. C. [3 ]
Yilmaz, Asli [1 ]
机构
[1] Univ Calgary, Dept Pathol & Lab Med, Calgary Lab Serv, Calgary, AB, Canada
[2] Univ Calgary, Dept Med, Calgary, AB, Canada
[3] Tom Baker Canc Clin, Dept Oncol, Calgary, AB, Canada
关键词
tertiary pattern; tertiary grade; Gleason pattern 5; Gleason grade 5; Gleason score; prostate biopsy; prostate cancer; RADICAL PROSTATECTOMY; PROGNOSTIC-SIGNIFICANCE; UPDATED PROTOCOL; SPECIMENS; GRADE; HETEROGENEITY; CARCINOMAS; PATHOLOGY; NOMOGRAM; SCORE-7;
D O I
10.1097/PAS.0b013e31817fb3bd
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Significance of tertiary Gleason pattern/grade 5 oil prostatectomy has been studied, but its significance on biopsy remains uncertain. Recent International Society of Urological Pathology consensus conference recommended that biopsy Gleason score is generated by adding tertiary grade 5 to the primary grade. We examined the preoperative clinical and biopsy findings in 53 patients with biopsy tertiary pattern 5 and 119 patients with primary/secondary biopsy pattern 5. Prostatectomy findings and prostate-specific antigen (PSA) failure rates were compared ill Surgically treated patients. Cause-specific and all-cause mortality were compared in patients treated nonsurgically. At presentation, age, gland volume, PSA, and biopsy cancer Volume were similar in patients with tertiary and primary/secondary grade 5. Only 20 patients underwent prostatectomy and 152 were treated nonsurgically. Regardless of the pattern, patients treated by prostatectomy were younger (P = 0.003), had lower PSA (P = 0.001), and less-cancer oil biopsy (P = 0.0001). Prostatectomy findings and PSA failures were not significantly different in patients with tertiary grade 5 versus primary/secondary pattern 5. In nonsurgically treated patients, patients with primary pattern 5 compared with those with tertiary pattern 5 had a significantly higher risk of all-cause mortality [adjusted hazard ratio (HR): 2.33, 95% confidence interval (Cl): 1.10-4.90, P = 0.026] and cause-specific mortality (adjusted HR: 7.52, 95% CI: 2.84-19.87, P < 0.001), In contrast, patients with secondary pattern 5 had a comparable all-cause mortality risk to patients with tertiary pattern 5 (adjusted HR: 1.04, 95% CI: 0.47-2.32, P = 0.92), but had a marginally higher risk of cause-specific mortality than patients with tertiary pattern 5 (adjusted HR: 2.13, 95% CI: 0.75-6.10, P = 0.16).
引用
收藏
页码:233 / 240
页数:8
相关论文
共 32 条
[1]   HETEROGENEITY OF PROSTATE-CANCER IN RADICAL PROSTATECTOMY SPECIMENS [J].
AIHARA, M ;
WHEELER, TM ;
OHORI, M ;
SCARDINO, PT .
UROLOGY, 1994, 43 (01) :60-66
[2]   Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens [J].
Amin, M ;
Boccon-Gibod, L ;
Egevad, L ;
Epstein, JI ;
Humphrey, PA ;
Mikuz, G ;
Newling, D ;
Nilsson, S ;
Sakr, W ;
Srigley, JR ;
Wheeler, TM ;
Montironi, R .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2005, 39 :20-33
[3]  
Amin MB, 1996, AM J CLIN PATHOL, V105, P667
[4]  
AMIN MB, 2004, GLEASON GRADING PROS, P101
[5]   Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer update panel report and recommendations for a standard in the reporting of surgical outcomes [J].
Cookson, Michael S. ;
Aus, Gunnar ;
Burnett, Arthur L. ;
Canby-Hagino, Edith D. ;
D'Amico, Anthony V. ;
Dmochowski, Roger R. ;
Eton, David T. ;
Forman, Jeffrey D. ;
Goldenberg, S. Larry ;
Hernandez, Javier ;
Higano, Celestia S. ;
Kraus, Stephen R. ;
Moul, Judd W. ;
Tangen, Catherine ;
Thrasher, J. Brantley ;
Thompson, Ian .
JOURNAL OF UROLOGY, 2007, 177 (02) :540-545
[6]   The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma [J].
Epstein, JI ;
Allsbrook, WC ;
Amin, MB ;
Egevad, LL ;
Bastacky, S ;
Beltrán, AL ;
Berner, A ;
Billis, A ;
Boccon-Gibod, L ;
Cheng, L ;
Civantos, F ;
Cohen, C ;
Cohen, MB ;
Datta, M ;
Davis, C ;
Delahunt, B ;
Delprado, W ;
Eble, JN ;
Foster, CS ;
Furusato, M ;
Gaudin, PB ;
Grignon, DJ ;
Humphrey, PA ;
Iczkowski, KA ;
Jones, EC ;
Lucia, S ;
McCue, PA ;
Nazeer, T ;
Oliva, E ;
Pan, CC ;
Pizov, G ;
Reuter, V ;
Samaratunga, H ;
Sebo, T ;
Sesterhenn, I ;
Shevchuk, M ;
Srigley, JR ;
Suzigan, S ;
Takahashi, H ;
Tamboli, P ;
Tan, PH ;
Têtu, B ;
Tickoo, S ;
Tomaszewski, JE ;
Troncoso, P ;
Tsuzuki, T ;
True, LD ;
van der Kwast, T ;
Wheeler, TM ;
Wojno, KJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) :1228-1242
[7]  
EPSTEIN JI, 2002, PROSTATE BIOPSY INTE, P154
[8]   Recommendations for the reporting of prostate carcinoma [J].
Epstein, Jonathan I. ;
Srigley, John ;
Grignon, David ;
Humphrey, Peter .
HUMAN PATHOLOGY, 2007, 38 (09) :1305-1309
[9]  
Gleason D., 1990, PATHOLOGY PROSTATE, P83
[10]   HISTOLOGIC GRADING OF PROSTATE-CANCER - A PERSPECTIVE [J].
GLEASON, DF .
HUMAN PATHOLOGY, 1992, 23 (03) :273-279